It is tempting to speculate that drugs specifically targeting these non‐classical monocytes (but not TEMs) may synergize with IFN‐γ gene therapy in B‐ALL and possibly other tumors. Here, IFNG is linked to precursor B-cell acute lymphoblastic leukemia.